GENOSKIN

Genoskin is a pioneering contract research organization that leverages ethically sourced human skin to accelerate the development of biotherapies, vaccines, medical devices, and cosmetics. By integrating advanced technologies like transcriptomics, spatial biology, and bioinformatics with our ex vivo human skin models, we offer a robust platform for predicting compound efficacy and safety before human trials. Our models provide unparalleled insights into substance interactions, absorption, irritation, and overall skin response, reducing time-to-market and minimizing development risks. Committed to ethical research, we replace animal testing with human-relevant data, driving innovation in the biomedical, cosmetics, and skincare products industry

Skin explant,vaccine development,cosmetics testing ,mast cells ,contract research organization (cro),medical devices testing ,toxicity testing ,injection site reactions,live human tissue,preclinical drug development ,early-phase development,beauty products testing,human skin models,ex vivo skin models ,transcriptomic analysis,preclinical studies,nonclinical testing ,and biologics testing

Genoskin operates in the Biotechnology research industry.

Genoskin's revenue is 1m - 10m

Genoskin has 11 - 50 employees.